Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

AgelessRx Publishes Blog Post Highlighting the Potential Benefits of LDN and NAD+ Therapy for Battling Long COVID

Ann Arbor, MI – As the world grapples with the lingering effects of the COVID-19 pandemic, a growing subset of individuals continues to face the challenge of Long COVID - a condition characterized by persistent symptoms that last weeks, months, or even years after the acute phase of the illness. AgelessRx, a longevity-focused telemedicine platform, has published a blog post that brings attention to innovative therapies, including Low Dose Naltrexone (LDN) and NAD+ (Nicotinamide Adenine Dinucleotide), that may offer relief to those suffering from the debilitating effects of Long COVID.

Understanding the Scope of Long COVID

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), has been reported to affect nearly 1 in 8 individuals who experience COVID-19, according to leading health organizations. Symptoms range from fatigue, brain fog, and joint pain to severe cardiovascular and neurological complications. With limited treatment options available, many patients find themselves navigating uncharted territory, seeking hope and solutions for recovery. Recognizing this unmet need, AgelessRx is championing the exploration of therapies that could provide meaningful relief.

The Promise of LDN

Low Dose Naltrexone (LDN) has gained attention for its potential to modulate the immune system and reduce inflammation - key factors believed to contribute to the symptoms of Long COVID. Originally used to treat opioid addiction in higher doses, LDN in microdoses has been found to have anti-inflammatory and neuroprotective properties. Preliminary studies suggest that LDN may alleviate symptoms such as fatigue, pain, and cognitive impairment.

NAD+: The Cellular Powerhouse

Another therapeutic option showing potential is NAD+ therapy. NAD+, a critical coenzyme found in every cell of the body, plays a vital role in energy production, DNA repair, and cellular resilience. Research suggests that Long COVID may deplete cellular energy reserves, exacerbating symptoms such as fatigue and brain fog. Administered via injections, NAD+ supplementation has been linked to improved energy levels, mental clarity, and a reduction in oxidative stress.

Empowering Patients with Access and Education

AgelessRx’s mission extends beyond providing innovative treatments; the company is committed to empowering patients through education and personalized care. Their telemedicine platform offers convenient access to licensed medical professionals who specialize in longevity therapies, including LDN and NAD+.

To further support their initiative, AgelessRx has launched an educational campaign on the potential benefits of LDN and NAD+ for Long COVID. Resources include detailed longevity blog posts, patient testimonials, and ongoing research updates. AgelessRx remains at the forefront of advancing these therapies, advocating for expanded clinical studies and broader patient access.

About AgelessRx

AgelessRx is at the forefront of the longevity revolution, offering cutting-edge solutions and preventive treatments aimed at extending life expectancy and enhancing healthspan. Through its online platform, AgelessRx provides easy access to innovative healthcare services, with an emphasis on customer satisfaction, affordability, and the pursuit of a future where extended healthspan is a reality for everyone.

Email: press@agelessrx.com

Media Contact

Name
AgelessRx
Contact name
Anar Isman
Contact phone
650-503-9990
Contact address
2370 E Stadium Blvd #2049
City
Ann Arbor
State
MI
Zip
48104
Country
United States
Url
https://www.agelessrx.com/

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.